Eleonora Ghisoni
A5083131544- Cancer Immunotherapy and Biomarkers
- Ovarian cancer diagnosis and treatment
- Immunotherapy and Immune Responses
- Hepatitis B Virus Studies
- CAR-T cell therapy research
- Immune Cell Function and Interaction
- Nanoplatforms for cancer theranostics
- Cancer Genomics and Diagnostics
- Health Systems, Economic Evaluations, Quality of Life
- Economic and Financial Impacts of Cancer
- PARP inhibition in cancer therapy
- Lung Cancer Research Studies
- Lung Cancer Treatments and Mutations
- Brain Metastases and Treatment
- Neuroendocrine Tumor Research Advances
- Radiomics and Machine Learning in Medical Imaging
- Single-cell and spatial transcriptomics
- Advanced Breast Cancer Therapies
- Intraperitoneal and Appendiceal Malignancies
- Cancer survivorship and care
- Statistical Methods in Clinical Trials
- Cancer, Lipids, and Metabolism
- Endometrial and Cervical Cancer Treatments
- Immune cells in cancer
- Virus-based gene therapy research
University of Lausanne
2019-2024
Ludwig Cancer Research
2019-2024
Swiss Cancer Center Léman
2024
University Hospital of Lausanne
2021-2023
University of Turin
2017-2020
Candiolo Cancer Institute
2017-2020
Fondazione Piemontese per la Ricerca sul Cancro Onlus
2018-2020
Istituti di Ricovero e Cura a Carattere Scientifico
2018-2020
Abstract Developing strategies to inflame tumors is critical for increasing response immunotherapy. Here, we report that low-dose radiotherapy (LDRT) of murine promotes T-cell infiltration and enables responsiveness combinatorial immunotherapy in an IFN-dependent manner. Treatment efficacy relied upon mobilizing both adaptive innate immunity depended on cytotoxic CD4+ CD8+ T cells. LDRT elicited predominantly cells with features exhausted effector cells, a subset expressing NKG2D exhibiting...
Immune checkpoint inhibitors (ICIs) have revolutionised cancer therapy but frequently cause immune-related adverse events (irAEs). Description of late-onset and duration irAEs in the literature is often incomplete.To investigate reporting incidence long-lasting irAEs, we reviewed all registration trials leading to ICI's approval by US FDA and/or EMA up December 2019. We analysed real-world data from lung (LC) melanoma (Mel) patients treated with approved ICIs at University Hospital Lausanne...
Abstract Expansion of antigen-experienced CD8 + T cells is critical for the success tumour-infiltrating lymphocyte (TIL)-adoptive cell therapy (ACT) in patients with cancer 1 . Interleukin-2 (IL-2) acts as a key regulator cytotoxic functions by promoting expansion and capability 2,3 Therefore, it essential to comprehend mechanistic barriers IL-2 sensing tumour microenvironment implement strategies reinvigorate responsiveness antitumour responses. Here we report that prostaglandin E2 (PGE 2...
Adoptive cell therapy (ACT) using ex vivo–expanded tumor-infiltrating lymphocytes (TILs) can eliminate or shrink metastatic melanoma, but its long-term efficacy remains limited to a fraction of patients. Using longitudinal samples from 13 patients with melanoma treated TIL-ACT in phase 1 clinical study, we interrogated cellular states within the tumor microenvironment (TME) and their interactions. We performed bulk single-cell RNA sequencing, whole-exome spatial proteomic analyses pre-...
In this study, we investigate mechanisms leading to inflammation and immunoreactivity in ovarian tumors with homologous recombination deficiency (HRD). BRCA1 loss is found lead transcriptional reprogramming tumor cells cell-intrinsic involving type I interferon (IFN) stimulator of IFN genes (STING). BRCA1-mutated (BRCA1mut) are thus T cell inflamed at baseline. Genetic deletion or methylation DNA-sensing/IFN CCL5 chemokine identified as a potential mechanism attenuate inflammation....
9504 Background: NIVO (anti–PD-1 antibody) is approved as monotherapy and in combination with either RELA (anti–LAG-3 or IPI (anti–CTLA-4 for the treatment of patients (pts) advanced melanoma. RELATIVITY-048 (NCT03459222) a phase 1/2, nonrandomized trial evaluating immuno-oncology (I-O) triplets, including + IPI, pts select solid tumors. This analysis from focused on use melanoma cohort first disclosure study. Methods: Pts were treated first-line 480 mg Q4W 160 1 mg/kg Q8W until progression...
To assess time trends in the inclusion of health-related quality life (QoL) among study endpoints and reporting QoL results publications, randomised phase III oncology trials published between 2017 2021 were compared with previous 5 years. All issues 2012 by 11 major journals handsearched for primary publications adult patients solid tumours. Trials 2017-2021 2012-2016 three endpoints: (1) proportion including out all eligible publications; (2) presenting those (3) data publications. 388 446...
Optimal cytoreduction (macroscopic Residual Tumor, RT = 0) is the best survival predictor factor in epithelial ovarian cancer (EOC). It doesn't exist a consolidated criteria to predict optimal surgical resection at interval debulking surgery (IDS). The aim of this study develop predictive model complete IDS. We, retrospectively, analyzed 93 out 432 patients, with advanced EOC, underwent neoadjuvant chemotherapy (NACT) and IDS from January 2010 December 2016 two referral centers. correlation...
Relapsed epithelial ovarian cancer (EOC) is frequently treated with pegylated liposomal doxorubicin (PLD). Unfortunately, most patients do not benefit from treatment. Prediction of response crucial to optimize PLD use and avoid unnecessary toxicities. We aimed at assessing the value topoisomerase II alpha (TOP2A) expression as predictive marker PLD-based therapy in relapsed EOCs. retrospectively analyzed Formalin Fixed Paraffin Embedded (FFPE) tissues 101 platinum resistant (PR) or partially...
Immune-checkpoint blockade (ICB) has shown significant efficacy across various tumor types. However, tumors with low intraepithelial T-cell infiltration, often referred to as cold tumors, are expected yield poor responsiveness ICB. We investigated the potential of low-dose radiotherapy (LDRT) enhance ICB responses in 25 patients multimetastatic immuneexcluded solid through a multi-cohort phase I clinical trial (RACIN). Primary endpoint was determine safety and tolerability combination...